Breakout Setups
ZYME appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
ZYMEWORKS INC (ZYME) Stock Price & Overview
NASDAQ:ZYME • US98985Y1082
Current stock price
27.84 USD
+0.86 (+3.19%)
Last:
The current stock price of ZYME is 27.84 USD. Today ZYME is up by 3.19%. In the past month the price increased by 14.23%. In the past year, price increased by 134%.
ZYME Key Statistics
52-Week Range10.86 - 28.49
Current ZYME stock price positioned within its 52-week range.
1-Month Range23.08 - 27.44
Current ZYME stock price positioned within its 1-month range.
- Market Cap
- 2.053B
- P/E
- N/A
- Fwd P/E
- 32.29
- EPS (TTM)
- -1.08
- Dividend Yield
- N/A
ZYME Stock Performance
Today
+3.19%
1 Week
+3.77%
1 Month
+14.23%
3 Months
+14.96%
Longer-term
6 Months +46.63%
1 Year +134.00%
2 Years +214.45%
3 Years +221.19%
5 Years -17.04%
10 Years N/A
ZYME Stock Chart
ZYME Stock Screens
ZYME currently appears in the following ChartMill screener lists.
ZYME Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ZYME. When comparing the yearly performance of all stocks, ZYME is one of the better performing stocks in the market, outperforming 93.44% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ZYME Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ZYME. ZYME has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ZYME Earnings
On March 2, 2026 ZYME reported an EPS of -0.55 and a revenue of 2.52M. The company missed EPS expectations (-29.54% surprise) and missed revenue expectations (-81.84% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateMar 2, 2026
PeriodQ4 / 2025
EPS Reported-$0.55
Revenue Reported2.515M
EPS Surprise -29.54%
Revenue Surprise -81.84%
ZYME Forecast & Estimates
20 analysts have analysed ZYME and the average price target is 40.88 USD. This implies a price increase of 46.83% is expected in the next year compared to the current price of 27.84.
For the next year, analysts expect an EPS growth of 179.83% and a revenue growth 138.52% for ZYME
Analysts
Analysts85
Price Target40.88 (46.84%)
EPS Next Y179.83%
Revenue Next Year138.52%
ZYME Groups
Sector & Classification
ZYME Financial Highlights
Over the last trailing twelve months ZYME reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS increased by 22.3% compared to the year before.
Income Statements
Revenue(TTM)105.97M
Net Income(TTM)-81.13M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.41% | ||
| ROE | -30.22% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-77.42%
Sales Q2Q%-91.9%
EPS 1Y (TTM)22.3%
Revenue 1Y (TTM)38.87%
ZYME Ownership
Ownership
Inst Owners94.12%
Shares73.75M
Float69.56M
Ins Owners0.95%
Short Float %6.41%
Short Ratio6.84
ZYME Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.06 | 371.899B | ||
| AMGN | AMGEN INC | 15.24 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.82 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.77 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.11 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.11 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.17 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.83 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.61 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZYME
Company Profile
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 264 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Company Info
IPO: 2019-06-24
ZYMEWORKS INC
108 Patriot Drive, Suite A
Middletown DELAWARE V6H 3V9 US
CEO: Ali Tehrani
Employees: 264
Phone: 13026587581
ZYMEWORKS INC / ZYME FAQ
What does ZYMEWORKS INC do?
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 264 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
What is the stock price of ZYMEWORKS INC today?
The current stock price of ZYME is 27.84 USD. The price increased by 3.19% in the last trading session.
Does ZYME stock pay dividends?
ZYME does not pay a dividend.
What is the ChartMill rating of ZYMEWORKS INC stock?
ZYME has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting ZYME stock to perform?
20 analysts have analysed ZYME and the average price target is 40.88 USD. This implies a price increase of 46.83% is expected in the next year compared to the current price of 27.84.
Is ZYMEWORKS INC (ZYME) expected to grow?
The Revenue of ZYMEWORKS INC (ZYME) is expected to grow by 138.52% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of ZYMEWORKS INC (ZYME) stock?
The outstanding short interest for ZYMEWORKS INC (ZYME) is 6.41% of its float.